Other names: v-raf murine sarcoma viral oncogene homolog B1; BRAF1; RAFB1 HGNC (Hugo): BRAF Location: 7q34 Local order: Between the NDUFB2 and MRPS33 genes. 
Protein

Note
The real sequence A31 G32 A33 was erroneously considered R31 P32. As the A33 was missing in previous sequences, some articles have erroneously assigned wrong numbers to coding mutations and amino acids (i.e. V599E mutation instead of V600E).
Description
Amino acids: 766. Molecular Weight: 84436 Daltons. The BRAF gene is a proto-oncogene that belongs to the serine/threonine kinase family. It is also a member of the RAF Subfamily together with the ARAF and RAF1 genes.
Expression
BRAF is expressed in most tissues with high expression in neuronal tissue.
Localisation
Cytoplasmic.
Function
BRAF is a serine/threonine kinase that belongs to the RAS/RAF/MEK/ERK/MAPK pathway, which is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. RAS is inactive when binded to GDP, but when it binds to GTP becomes active and promotes phosphorylation and activation of BRAF and the activation of the pathway signal. Several genes have been found to be activated by this pathway, among them, cyclin D1, cyclin D2 and cyclin D3 (selfsufficiency in growth), VEGF (angiogenesis), c-myc (insensitivity to antigrowth signals), b3-integrin (tissue invasion and metastasis) and mdm2 (apoptosis evasion, limitless replicative potential and angiogenesis).
Homology
BRAF shares three conserved regions (CR1, CR2 and CR3) with the other two RAF genes: ARAF and RAF1. CR1, which has 131 aa, contains the cysteine-rich domain (CRD) and most of the Ras binding domain (RBD). These two domains bind to RAS-GTP. CR2, which has 16 aa, is rich in serine and threonine residues, including S365 as an inhibitory phosphorylation site. Finally CR3, which has 293 aa and has the kinase domain, contains also the G-loop GXGXXG motif (highly conserved in most of the human kinases), the activation segment and the regulatory phosphorylation sites S446, S447, D448, D449, T599 and S602.
Mutations
Note
Single nucleotide polymorphism (SNP) found in BRAF: A1023G (P341P); A1227G (S409S); A1383G (Q461Q); A1797C (T599T); A1929G (G643G); G2272A (G758R).
Germinal
No germinal mutations described.
Somatic
BRAF presents somatic mutations in different sort of tumors, predominantly in malignant melanoma, sporadic colorectal tumors showing mismatch repair defects in microsatellites (MSI), low-grade ovarian serous carcinoma and thyroid papillary cancer. 80% of these mutations correspond to the hotspot transversion mutation T1799A that causes the amino acidic substitution V600E. The other 20% accounts for a wide variable range of missense mutations and all of them reside in the glycines of the G-loop in the exon 11 or in the activation segment in exon 15 near the V600. The mutation V600E confers transformant activity to the cells because it mimics the phosphorylation of T599 and/or S602 in the activation segment and so BRAF rests constitutively active in a RAS independent manner. Mutations in or NRAS are not concomitant with the BRAF mutation V600E. This mutation has not been found in other tumors like gastric cancer, endometrial cancer, uveal melanoma, biliary tract cancer or hepatocellular carcinoma. 
Implicated in
Melanoma
Note BRAF is mutated in 70% of malignant melanomas. The mutation V600E is an early event and alone is insufficient for the development of melanoma as it is present in 80% of primary melanomas and 80% of nevi, which are the first lesions associated with this tumor. No BRAF mutations are associated with uveal melanoma.
Colorectal cancer
Note BRAF mutation V600E is associated with mismatch repair deficiency (MSI) and found in 40% of the cases while in mismatch repair proficient tumors (MSS) the frequency is around 5%. Gastric and endometrial MSI and MSS tumors do not have BRAF mutations. In sporadic MSI colon cases this mutation is found in proximal colon tumors with MLH1 methylation (80% of cases), while in tumors from the hereditary nonpolyposis colorectal cancer (HNPCC), either with MLH1, MSH2 or MSH6 germline mutations or none, no BRAF mutations are detected. Because of this it has been proposed the use of the BRAF V600E mutation for HNPCC diagnostic as a exclusion criteria for germline mutation in mismatch repair genes. Prognosis Even though its association with sporadic MSI suggest BRAF as a good prognosis factor, it has been also associated to metastatic colorectal MSS cancers. In this cases, BRAF associates with poor prognosis.
Ovarian cancer
Note
The only BRAF mutation is V600E which is found in 30% of low-grade serous carcinoma and borderline tumors. The mutation seems to occur very early in the development. High-grade tumors do not show BRAF mutations.
Thyroid cancer
Note
In thyroid papillary cancer the only BRAF mutation present is V600E with a frequency around 50%. The K601E mutation has also been found in some cases of the follicular variant of thyroid cancer.
